HMPL-523 is a novel, highly selective and potent small molecule oral inhibitor targeting spleen tyrosine kinase, also known as Syk, a key component in B-cell receptor signalling. Preparations
TheraKine has developed sustained release delivery technology platforms for injectable local delivery of biologic agents and live cells. Cell Care uses stem cells to treat degenerative and inflammatory
Ketamine, which has been extensively used as an intravenous anesthetic for many years, has been also reported to be effective as a rapid treatment for a variety of
As part of the three-year agreement, AMRI gains access to NYCNMR’s nanoscale therapeutic and formulation services. NYCNMR’s customers will benefit from AMRI’s suite of integrated drug discovery solutions,
An "orphan receptor" is structurally related to a family of proteins that are known to act as functional cell-surface receptors but whose ligand has not yet been identified.
New investor Deerfield Management Company led the financing, which also included participation from new investor Casdin Capital as well as existing investors Fidelity Management and Research Company, WuXi
These tests will be used to help identify patients for MedImmune’s MEDI4893 and MEDI3902 clinical programs, which are being conducted within the COMBACTE consortium to explore the use
ThromboGenics hopes to be able to reduce the risk of disease progression to proliferative diabetic retinopathy (PDR) by inducing a total PVD using ocriplasmin. PDR is the major
The EORTC intergroup trial 1206:"A randomised phase II study to evaluate the efficacy and safety of chemotherapy vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic,
The MHRA conducted a site-specific inspection in November 2015 to evaluate whether the Group’s existing manufacturing processes and quality management systems had been effectively extended and implemented at
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.